Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Kalvista Pharmaceuticals Inc (NQ: KALV ) 10.00 +0.54 (+5.71%) Streaming Delayed Price Updated: 4:00 PM EDT, Sep 26, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Kalvista Pharmaceuticals Inc < Previous 1 2 3 4 5 Next > KalVista Pharmaceuticals Announces Nine Abstracts Accepted for Presentation at the HAEi Global Angioedema Forum (GAF) Today 6:30 EDT From KalVista Pharmaceuticals, Inc. Via Business Wire KalVista Pharmaceuticals to Participate in the 2024 Cantor Global Healthcare Conference September 10, 2024 From KalVista Pharmaceuticals, Inc. Via Business Wire KalVista Appoints Brian Piekos as Chief Financial Officer September 10, 2024 From KalVista Pharmaceuticals, Inc. Via Business Wire KalVista Pharmaceuticals Presents Sebetralstat Data at Bradykinin Symposium 2024 September 06, 2024 From KalVista Pharmaceuticals, Inc. Via Business Wire KalVista Pharmaceuticals Reports First Fiscal Quarter Results and Provides Operational Update September 05, 2024 From KalVista Pharmaceuticals, Inc. Via Business Wire KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) September 04, 2024 From KalVista Pharmaceuticals, Inc. Via Business Wire KalVista Announces FDA Acceptance of New Drug Application for Sebetralstat for Oral On-Demand Treatment of Hereditary Angioedema September 03, 2024 From KalVista Pharmaceuticals, Inc. Via Business Wire KalVista Pharmaceuticals Announces Six Abstracts Accepted for Presentation at the 2024 Bradykinin Symposium August 29, 2024 From KalVista Pharmaceuticals, Inc. Via Business Wire KalVista Announces Validation of Marketing Authorization Application by the European Medicines Agency for Sebetralstat for Hereditary Angioedema August 15, 2024 From KalVista Pharmaceuticals, Inc. Via Business Wire KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) August 02, 2024 From KalVista Pharmaceuticals, Inc. Via Business Wire KalVista Pharmaceuticals Provides Operational Update and Fiscal Year Financial Results July 11, 2024 From KalVista Pharmaceuticals, Inc. Via Business Wire KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) July 02, 2024 From KalVista Pharmaceuticals, Inc. Via Business Wire KalVista Initiates KONFIDENT-KID Trial for On-demand Treatment of Hereditary Angioedema Attacks with Sebetralstat in Children Aged 2 to 11 June 27, 2024 From KalVista Pharmaceuticals, Inc. Via Business Wire KalVista Submits New Drug Application to FDA for Sebetralstat as First Oral On-demand Treatment for Hereditary Angioedema June 18, 2024 From KalVista Pharmaceuticals, Inc. Via Business Wire KalVista Pharmaceuticals Presents Data at Eastern Allergy Conference 2024 and the Japanese Dermatological Association 2024 June 06, 2024 From KalVista Pharmaceuticals, Inc. Via Business Wire KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) June 04, 2024 From KalVista Pharmaceuticals, Inc. Via Business Wire KalVista Pharmaceuticals Presents Data on Persisting Unmet Needs in Hereditary Angioedema at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2024 June 03, 2024 From KalVista Pharmaceuticals, Inc. Via Business Wire KalVista Pharmaceuticals Announces New England Journal of Medicine Publishes Oral Sebetralstat Phase 3 Data Demonstrating its Potential to Transform the Treatment Landscape for People with Hereditary Angioedema May 31, 2024 From KalVista Pharmaceuticals, Inc. Via Business Wire KalVista Pharmaceuticals Announces Ten Abstracts Accepted for Presentation at the European Academy of Allergy and Clinical Immunology Congress 2024 May 24, 2024 From KalVista Pharmaceuticals, Inc. Via Business Wire KalVista Pharmaceuticals to Present at Upcoming Investor Conferences May 21, 2024 From KalVista Pharmaceuticals, Inc. Via Business Wire KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) May 02, 2024 From KalVista Pharmaceuticals, Inc. Via Business Wire KalVista Pharmaceuticals Highlights Strategic Plans for Coming Fiscal Year May 01, 2024 From KalVista Pharmaceuticals, Inc. Via Business Wire KalVista Pharmaceuticals Appoints William C. Fairey to Board of Directors April 22, 2024 From KalVista Pharmaceuticals, Inc. Via Business Wire KalVista Pharmaceuticals to Present at 23rd Annual Needham Virtual Healthcare Conference April 03, 2024 From KalVista Pharmaceuticals, Inc. Via Business Wire KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) April 02, 2024 From KalVista Pharmaceuticals, Inc. Via Business Wire KalVista Pharmaceuticals Presents Real-World Data on Burden of Treatment and HAE Attack Journey at the 2024 HAEi Regional Conference Americas March 18, 2024 From KalVista Pharmaceuticals, Inc. Via Business Wire KalVista Pharmaceuticals Awarded UK Promising Innovative Medicine (PIM) Designation for Sebetralstat March 12, 2024 From KalVista Pharmaceuticals, Inc. Via Business Wire KalVista Pharmaceuticals Reports Third Fiscal Quarter Results and Provides Operational Update March 11, 2024 From KalVista Pharmaceuticals, Inc. Via Business Wire KalVista Pharmaceuticals to Present HAE Attack Journey Data at 2024 HAEi Regional Conference Americas March 08, 2024 From KalVista Pharmaceuticals, Inc. Via Business Wire KalVista Pharmaceuticals Announces Appointment of Benjamin L. Palleiko as Chief Executive Officer March 07, 2024 From KalVista Pharmaceuticals, Inc. Via Business Wire < Previous 1 2 3 4 5 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.